Daniel S. Longyhore, PharmD

home / authors / daniel-s-longyhore-pharmd

Articles

July 7th 2009

Lipid Profile Changes Associated With Changing Available Formulary Statins: Removing Higher Potency Agents

Daniel S. Longyhore, PharmD Casey McNulty Stockton, PharmD Marie Roke Thomas, PhD

With the exception of high-density lipoprotein cholesterol, fasting lipid profiles were not significantly changed after higher potency statins were removed from prescription formularies.

Latest Updated Articles

Transgender | Image credit: Olga Tsikarishvili - stock.adobe.com

Published: August 18th 2025 | Updated: August 25th 2025

Conditional Economic Incentives Could Be Effective in Improving Adherence to Long-Acting PrEP in Transgender Adults

Semaglutide | Image credit: Peter Hansen - stock.adobe.com

Published: August 19th 2025 | Updated: August 22nd 2025

Semaglutide Not Associated With Increased Risk of Eye Disorders

On-body delivery system | Image credit: Enable Injections

Published: June 6th 2025 | Updated: August 18th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

drug shortages in the US | Image credit: OntheRun Photo - stock.adobe.com

Published: June 27th 2025 | Updated: July 1st 2025

Report Reveals Mounting Burdens of Drug Shortages on US Health System

Published: February 20th 2025 | Updated: February 21st 2025

Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP

Hands holding pack of cigarettes | Image credit: Nopphon – stock.adobe.com

Published: January 16th 2025 | Updated: January 29th 2025

FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

Do Not Sell My Information

Terms & Conditions